Effect of suplatast tosilate on goblet cell metaplasia in patients with asthma
Authors: Hoshino, M.; Fujita, Y.; Saji, J.; Inoue, T.; Nakagawa, T.; Miyazawa, T.
Source: Allergy, Volume 60, Number 11, November 2005 , pp. 1394-1400(7)
Publisher: Blackwell Publishing
Key:
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
Background: Goblet cell metaplasia is a pathologic characteristic of asthma, associated with excess mucus secretion. Interleukin (IL)-4 and IL-13 plays an important role in mucus hypersecretion. Suplatast tosilate (suplatast), an antiallergic agent, is a Th2 cytokine inhibitor that suppresses the synthesis of IL-4, IL-5, IL-13, and eosinophilic airway inflammation. Objective: We examined the effects of suplatast on mucus production in bronchial biopsy specimens taken from asthmatic subjects. Methods: Oral suplatast 300 mg daily, or placebo was administered for 3 months in a double-blind, parallel-group study in 25 patients with asthma. Biopsy specimens were evaluated at before and after treatment for alcian blue/period acid-Schiff (AB/PAS), MUC5AC staining in bronchial epithelium and IL-4+, IL-13+ cells as well as inflammatory cells in lamina propria. Results: There were significant decreases in the percentage of AB/PAS (P < 0.01) and MUC5AC (P < 0.01) stained area in the suplatast group. These changes were accompanied by significant decreases in IL-4+ and IL-13+ cells in suplatast-treated subjects. Additionally, we have observed that the number of infiltrating eosinophils and CD4+ T cells significantly decreased. Conclusions: These findings suggest that suplatast prevents goblet cell metaplasia through modulation of Th2 cytokine production and the recruitment of eosinophils and CD4+ T cells in the asthmatic airways.Keywords: airway inflammation; bronchial asthma; goblet cell metaplasia; interleukin-4; interleukin-13; mucus production; suplatast tosilate
Document Type: Research article
DOI: 10.1111/j.1398-9995.2005.00897.x
Key:
- Free Content
- New Content
- Subscribed Content
- Free Trial Content

Click here for Page Help